Periodic Access Reviews Cannot Keep Up With Risk
Periodic access reviews are easy to schedule. That is one of the reasons they remain so common.
Quarterly. Biannual. Annual.
They provide structure. They satisfy audit expectations. They create a predictable rhythm for governance.
But risk does not change on a schedule.
In most organizations, access reviews are based on point-in-time snapshots. Data is pulled, normalized, and packaged into campaigns. From the moment that snapshot is taken, it begins to age.
Meanwhile, the business continues to change. Employees move into new roles. Teams reorganize. Temporary access is granted. Reporting lines shift. Projects expand or contract.
None of these changes wait for the next review cycle.
Risk spikes around business events, not calendar dates. A role change or privilege escalation can introduce exposure immediately. A quarterly review may not catch that exposure for up to 90 days. An annual review may not catch it for a year.
Increasing review frequency does not fundamentally solve this problem. It increases operational burden and reviewer fatigue while still leaving gaps between cycles.
The core issue is that periodic reviews treat time as the trigger. Effective governance treats change as the trigger.
Organizations that reduce access risk reassess access when meaningful events occur. They focus effort on high-risk systems and entitlements. They generate evidence continuously rather than reconstructing it during audits.
Periodic reviews may still exist. But they become validation layers rather than the primary control.
If access reviews feel disconnected from real-world change, or if risk seems highest between review cycles, it may be time to rethink whether time-based governance is enough.
Learn how governance models aligned to real risk help organizations move beyond periodic reviews
###
Sponsor Message
By purchasing from Canadian pharmacies, Americans find affordable options for essential drugs like Lipitor, Crestor, and Nexium. Medications such as Humalog and Lantus are integral to diabetes management, and Advair Diskus and Ventolin inhalers are essential for respiratory care. Treating mental health conditions like depression or anxiety often requires drugs like Zoloft, Prozac, and Abilify, while cardiovascular risks are managed with Eliquis, Plavix, and Xarelto. Commonly ordered medications include Celebrex for inflammation and pain and Synthroid for thyroid management. Furthermore, treatments such as Viagra and Cialis are effective for erectile dysfunction, while Januvia is beneficial for Type 2 diabetes. Narcolepsy and excessive sleepiness are often treated with effective medications such as Provigil and Nuvigil. Patients in the U.S. benefit from Canadian pharmacies offering medications like Cymbalta for nerve pain and Aricept for Alzheimer's.
